tetano
Editor, Senior Moderator
Pol Merkur Lekarski
. 2021 Jun 16;49(291):227-230.
The presence of anti-leucocyte antibodies in the plasma of convalescent women after SARS-CoV-2 infection as a reason for disqualification for plasma therapy - analysis based on a literature review
Dominika Wendlocha[SUP] 1 [/SUP], Aleksandra Janusz[SUP] 1 [/SUP], Joanna Janusz[SUP] 1 [/SUP], Patrycja Krolewska-Daszczynska[SUP] 1 [/SUP], Aleksandra Englisz[SUP] 1 [/SUP], Marta Smycz-Kubanska[SUP] 1 [/SUP], Aleksandra Mielczarek-Palacz[SUP] 1 [/SUP]
Affiliations
Abstract
According to the data from November 29 2020, the SARS-CoV-2 coronavirus was responsible for 61 866 635 cases of infections and 1 448 990 deaths worldwide, and the number is still growing rapidly. The main problem is the rapid increase in the number of patients with pneumonia complicated by respiratory failure. In the treatment of COVID- 19 patients, a significant effect of convalescent plasma (CP) therapy from convalescent patients with SARS-CoV-2 IgG neutralizing antibodies is indicated. After this procedure, the total duration of the infection was shortened and the clinical condition improved faster than in patients who did not receive this form of therapy. The aim of the study was to explain the cause disqualifying women with anti-leucocyte anitibodies as CP plasma donors for COVID-19 patients. However, according to the literature, 2% of patients who received plasma from convalescents developed Transfusion Related Acute Lung Injury (TRALI). The most common causes of TRALI are anti-leukocyte antibodies directed against Human Leukocyte Antigens (HLA) class I and II and against Human Neutrophil Antigens (HNA). Therefore, patients with COVID-19 may only be transfused with plasma from convalescent women with a history of pregnancy after testing negative for anti-leucocyte antibodies in the pre-plasmapheresis blood sample.
Keywords: SARS CoV-2 coronavirus; convalescent plasma; neutralizing antibodies.
. 2021 Jun 16;49(291):227-230.
The presence of anti-leucocyte antibodies in the plasma of convalescent women after SARS-CoV-2 infection as a reason for disqualification for plasma therapy - analysis based on a literature review
Dominika Wendlocha[SUP] 1 [/SUP], Aleksandra Janusz[SUP] 1 [/SUP], Joanna Janusz[SUP] 1 [/SUP], Patrycja Krolewska-Daszczynska[SUP] 1 [/SUP], Aleksandra Englisz[SUP] 1 [/SUP], Marta Smycz-Kubanska[SUP] 1 [/SUP], Aleksandra Mielczarek-Palacz[SUP] 1 [/SUP]
Affiliations
- PMID: 34218245
Abstract
According to the data from November 29 2020, the SARS-CoV-2 coronavirus was responsible for 61 866 635 cases of infections and 1 448 990 deaths worldwide, and the number is still growing rapidly. The main problem is the rapid increase in the number of patients with pneumonia complicated by respiratory failure. In the treatment of COVID- 19 patients, a significant effect of convalescent plasma (CP) therapy from convalescent patients with SARS-CoV-2 IgG neutralizing antibodies is indicated. After this procedure, the total duration of the infection was shortened and the clinical condition improved faster than in patients who did not receive this form of therapy. The aim of the study was to explain the cause disqualifying women with anti-leucocyte anitibodies as CP plasma donors for COVID-19 patients. However, according to the literature, 2% of patients who received plasma from convalescents developed Transfusion Related Acute Lung Injury (TRALI). The most common causes of TRALI are anti-leukocyte antibodies directed against Human Leukocyte Antigens (HLA) class I and II and against Human Neutrophil Antigens (HNA). Therefore, patients with COVID-19 may only be transfused with plasma from convalescent women with a history of pregnancy after testing negative for anti-leucocyte antibodies in the pre-plasmapheresis blood sample.
Keywords: SARS CoV-2 coronavirus; convalescent plasma; neutralizing antibodies.